MiMedx Group Inc (MDXG)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $468.42M
Last updated: Nov 17, 2026 at 11:05 AM ET
MiMedx Group Inc (MDXG) P/E Ratio & Valuation History
MiMedx Group (MDXG) trades at 106.0x trailing earnings and 1.5x sales. Its P/S of 1.5x is below its 5-year median of 2.5x. Its forward P/E is 19.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 443.6% higher over the next year. Its free cash flow yield is 4.1%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 106.0x |
| Forward P/E | 19.5x |
| Price to sales | 1.5x |
| Price to book | 2.2x |
| Price to FCF | 24.3x |
| EV/FCF | 17.9x |
| PEG | 2.9 |
| FCF yield | 4.1% |
Historical Medians
Against its 10-year medians, its P/S is 42.3% below 2.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.5x | 2.5x | 2.6x |
Valuation History
Over the 7 of the 10 year ends shown that have a P/E, its P/E ranged from 15.4x in 2025 to 100.9x in 2020. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $6.77 | 15.4x | 2.4x | 4.0x |
| 2024 | $9.62 | 33.2x | 4.1x | 7.4x |
| 2023 | $8.77 | 26.1x | 3.4x | 9.1x |
| 2022 | $2.78 | N/A | 1.2x | N/A |
| 2021 | $6.04 | N/A | 2.8x | 7.4x |
| 2020 | $9.08 | 100.9x | 4.0x | 10.8x |
| 2019 | $7.58 | 36.1x | 2.7x | 16.2x |
| 2018 | $1.79 | N/A | 0.5x | 3.8x |
| 2017 | $12.61 | 39.4x | 4.3x | 19.4x |
| 2016 | $8.86 | 40.3x | 4.3x | 7.6x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MDXG
What is MDXG's forward P/E ratio?
MiMedx Group has a forward P/E ratio of 19.5x.
Is MDXG stock overvalued?
GNG's valuation label for MDXG is Undervalued.
What is MDXG's price to sales ratio?
MiMedx Group has a price to sales ratio of 1.5x.
What is MDXG's PEG ratio?
MiMedx Group has a PEG ratio of 2.9.
MDXG pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors